FOLLOWING their development and validation of a colorimetric and fluorescent based Nucleic Acid Amplification Test (NAAT), Eurekan Biotech is also pioneering the deployment of a non-sequence based NAAT kit for rapid detection of COVID-19 variants in Africa.
The variant kits were recently assessed and tested on live COVID-19 variants which had already been sequenced and analysed with the high-end Illumina MiSeq and HiSeq genetic sequencing equipment at the African Center of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemers University, Ede, Osun State, Nigeria – under the leadership of Professor Christian Happi.
Nigeria has also seen an influx of a few COVID-19 variants of concern (VOC) among which were the popular B.1.1.7 (UK) variant which has a significant mutation (N501Y) in its spike protein. An emerging variant under investigation (VUI) which has been attributed to have emanated from Nigeria and partly UK – is the B.1.525 variant which notably has an E484K mutation – also conferring significant changes in the receptor binding domain of SARS-CoV-2.Some of these strains have been associated with efficient transmissibility of the virus because of their stickiness factor and ability to bind tightly with ACE-2 receptors on host cells with a slight possibility of being able to evade neutralizing antibodies in vaccinated and naturally immunized individuals.
While there is a need to keep up with testing and upholding other preventive measures – including vaccinations, there may be a need to keep up with public health surveillance and control of other COVID-19 variants of “serious” concern – such as the B.1.351 (South African) and B.1.617 (Indian) strains from seeping through Nigerian borders and ports of entry, due to international travel.
An adequate genetic sequencing of a single case sample may gulp up to $1,000 (one thousand US dollars) in analyses fees for equipment use and consumables. But Eurekan Biotech’s COVID-19 variant kit (CoVAMPTM Var) leverages on existing technology for Nucleic Acid Amplification Tests for a low cost assessment and detection of COVID-19 variants at about $50 (fifty US dollars) per test. Using the melt curve analytics of existing qPCR equipment which are accessible at most NCDC collaborating molecular labs for COVID-19 testing in Nigeria, an assessment of a few target polymorphisms or notable mutations of interest can be used to characterise COVID-19 variants with qPCR instruments currently utilised for SARS-COV-2 diagnostics.
Eurekan Biotech’s low cost rapid colorimetric COVID-19 NAAT kit (CoVAMPTM Colo) which was also recently validated at ACEGID and NCDC’s National Reference Laboratory (NRL) is being proposed for routine testing and confirmation of RDT-assessed wild-type SARS-COV-2 at resource limited non-PCR labs in Nigeria (mostly general hospitals and other secondary healthcare institutions).
- Adenmosun is founder/CEO of Eurekan Biotechnologies and DNAEnsemble. He can be reached via [email protected]
YOU SHOULD NOT MISS THESE HEADLINES FROM NIGERIAN TRIBUNE
We Have Not Had Water Supply In Months ― Abeokuta Residents
In spite of the huge investment in the water sector by the government and international organisations, water scarcity has grown to become a perennial nightmare for residents of Abeokuta, the Ogun State capital. This report x-rays the lives and experiences of residents in getting clean, potable and affordable water amidst the surge of COVID-19 cases in the state.